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Epidermal hyperplasiaFatty acid transport protein (FATP) 4 is one of a family of six FATPs that facilitate long- and very long-chain
fatty acid uptake. Mice lacking FATP4 are born with tight, thick skin and a defective epidermal barrier; they
die neonatally due to dehydration and restricted movements. Both the skin phenotype and the lethality are
rescued by transgene-driven expression of FATP4 solely in suprabasal keratinocytes. Here we show that
Fatp4 mutants exhibit epidermal hyperplasia resulting from an increased number of proliferating suprabasal
cells. In addition, barrier formation initiates precociously but never progresses to completion. To investigate
possible mechanisms whereby Fatp4 inﬂuences skin development, we identiﬁed misregulated genes in Fatp4
mutants. Remarkably, three members of the epidermal growth factor (EGF) family (Ereg, Areg, and Epgn)
showed increased expression that was associated with elevated epidermal activation of the EGF receptor
(EGFR) and STAT3, a downstream effector of EGFR signaling. Both Tyrphostin AG1478, an EGFR tyrosine
kinase inhibitor, and curcumin, an inhibitor of both STAT3 and EGFR, attenuated STAT3 activation/nuclear
translocation, reduced skin thickening, and partially suppressed the barrier abnormalities. These data
identify FATP4 activity as negatively inﬂuencing EGFR activation and the resulting STAT3 signaling during
normal skin development. These ﬁndings have important implications for understanding the pathogenesis of
ichthyosis prematurity syndrome, a disease recently shown to be caused by FATP4 mutations.0 S. Euclid Ave., St. Louis, MO
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The mature mammalian skin is a stratiﬁed epithelium derived
from the embryonic ectoderm; it is the ﬁrst line of defense against
mechanical and chemical trauma. The skin also functions as a barrier
to block the entry of microorganisms and to prevent the loss of body
hydration. During skin morphogenesis, several signaling pathways
participate in a series of inductive events that guide the separation of
the hair lineage from the epidermal lineage and promote epidermal
differentiation and stratiﬁcation (Fuchs and Raghavan, 2002; Millar,
2002).
Epidermal stratiﬁcation begins when proliferative basal cells
migrate suprabasally and exit the cell cycle, beginning a series of
steps culminating in corniﬁcation (Elias and Jackson, 1996). The ﬁrst
event is keratinization, the switch in intermediate ﬁlaments from a
keratins 5/14-containing network to a keratins 1/10-containing
network, permitting cells in the spinous layer to form a rigid
cytoskeleton. Secondly, keratohyalin granules containing proﬁlaggrin
are synthesized to facilitate the assembly of keratin bundles, formingthe granular layer. Thirdly, involucrin (IVL), loricrin, and other
proteins are cross-linked by transglutaminase, forming an insoluble
corniﬁed envelope beneath the cell membrane. Finally, lipid-enriched
lamellar bodies secrete their contents into the intercellular spaces of
the corniﬁed layer, completing the formation of a water-resistant
barrier. This progression from a proliferating basal cell to a terminally
differentiated, corniﬁed squamous cell occurs continuously through-
out life, as skin is a constantly regenerating organ (Fuchs and
Raghavan, 2002).
We previously identiﬁed an autosomal recessive mouse mutation
called wrinkle free (Moulson et al., 2003). Homozygous mutants are
born with taut and shiny skin, a thickened epidermis, a defective skin
barrier, and sparse hair follicles; neonates die due to dehydration and
restricted movements. By positional cloning, we found the mutation
to be caused by a spontaneous retrotransposon insertion into Slc27a4,
the gene encoding fatty acid transport protein (FATP) 4. One targeted
mutation in Slc27a4 (here referred to as Fatp4 for simplicity) shows an
identical phenotype (Herrmann et al., 2003), and another was
reported to cause very early embryonic lethality (Gimeno et al., 2003).
FATP4 is one of a family of six transmembrane proteins that
facilitate long- and very long-chain fatty acid uptake. FATP4 exhibits
acyl-CoA synthetase (ACS) activity and has been proposed to facilitate
uptake of fatty acids indirectly by mediating their esteriﬁcation to CoA
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acid transport functions identiﬁed for other FATPs, such as FATP1
(Richards et al., 2006; Schaffer and Lodish, 1994). FATP4 is widely
expressed, suggesting roles in many organs (Herrmann et al., 2001;
Moulson et al., 2003). In skin FATP4 is normally detected in basal and
suprabasal keratinocytes (MHL and JHM, unpublished data), with the
strongest expression in the granular layer of the epidermis (Moulson
et al., 2007). Suprabasal keratinocyte expression of a FATP4 transgene
in the epidermis rescues the neonatal lethality and ameliorates the
skin phenotype of Fapt4mutant mice, indicating crucial, skin-intrinsic
roles for FATP4 in the development of skin and its appendages
(Moulson et al., 2007).
The recent identiﬁcation of Fatp4 mutations in patients with
ichthyosis prematurity syndrome (Klar et al., 2009) makes an
understanding of the mechanism whereby the absence of FATP4
causes the wrinkle free phenotype in mice an especially important
goal. Here we characterized the skin abnormalities in Fatp4−/− mice
at the cellular level and found an increased number of proliferating
keratinocytes in the suprabasal layer. To identify possible mechanisms
that link the lack of FATP4 to speciﬁc defects in the development of
skin and its appendages, we carried out microarray analyses with
embryonic skin RNAs and found upregulation of several EGF family
ligands in Fatp4 mutant skin, together with increased activation of
STAT3, a downstream effector of the EGF receptor (EGFR) signaling
pathway. Furthermore, pharmacological blockade of EGFR and STAT3
activation suppressed epidermal hyperplasia in Fatp4 mutants, and
this correlated with reduced hyperproliferation. These data indicate
that the lack of FATP4 creates an environment, presumably via direct
effects on lipid metabolism and homeostasis, that promotes epider-
mal proliferation via overactivation of the EGFR and the downstream
STAT3 signaling pathways.
Materials and methods
Mice and skin barrier assays
Fatp4mutant and transgenic mice have been previously described
(Moulson et al., 2007; Moulson et al., 2003). Embryonic day (E) 15.5
to E17.5 embryos were dissected from pregnant females, with the
morning when the copulation plug was observed considered E0.5. For
inward permeability assays, embryos were stained in the dark at 37 °C
overnight in X-Gal solution (1 mg/ml X-Gal, 3 mM K4Fe(CN)6, 3 mM
K3Fe(CN)6, 1.3 mM MgCl2, 0.1 M NaH2PO4) at pH 4.5 as described
(Hardman et al., 1998). In some experiments embryoswere incubated
in a series of ascending and then descending concentrations of
methanol, equilibrated in phosphate buffered saline (PBS), and
stained brieﬂy in 1% toluidine blue in water followed by destaining
in PBS (Hardman et al., 1998). Stained samples were ﬁxed in 4%
paraformaldehyde in PBS at room temperature for 1 h to overnight.
For outward transepidermal water loss (TEWL) assays, embryos were
rinsed in PBS, blotted gently with a Kimwipe, and air-dried for 5 min.
The water loss through the dorsal or lateral skin wasmeasured using a
Vapometer (Delﬁn Technologies, Kuopio, Finland) with the sensor
chamber attached to a nail adaptor.
Immunohistochemistry
Embryos were ﬁxed at room temperature for 2 to 3 h in 4%
paraformaldehyde in PBS. To increase the penetration of ﬁxative,
E15.5 or older embryos were decapitated, and the abdominal cavity
was exposed. Fixed embryos at E14.5 were cut into halves along the
dorsal midline, embedded in parafﬁn, and sectioned parasagittally at
5 µm. For ﬁxed embryos at older stages, the dorsal skin was collected
for parafﬁn embedding.
Immunohistochemical analyses were performed using the perox-
idase Vectastain ABC kit (Vector Laboratories, Burlingame, CA) withDAB as a chromogen (Pierce, Rockford, IL) as described (Lin et al.,
2000), with some modiﬁcations. To retrieve antigens, rehydrated
sections were boiled in 10 mM citrate buffer (pH 6), Trilogy (Cell
Marque, Rocklin, CA), or 1 mM EDTA (pH 8). To block endogenous
biotin and avidin, the Avidin/Biotin blocking kit (Vector Laboratories)
was used before adding primary antibodies. The antigen retrieval
method and dilutions of primary antibodies used were as follows:
EDTA and 1:50 for phospho-STAT3 (Tyr705); EDTA and 1:100 with
tyramide ampliﬁcation for phospho-EGFR (Tyr1068); citrate and
1:100 for phospho-p44/42 MAP kinase (Thr202/Tyr204); citrate and
1:100 for phospho-p38 MAPK (Thr180/Tyr182); citrate and 1:100 for
phospho-SAPK/JNK (Thr183/Tyr185) (all antibodies were from Cell
Signaling Technology, Beverly, MA); Trilogy and 1:100 with tyramide
ampliﬁcation for JAK2 (phospho Y1007+Y1008) (Abcam, Cambridge,
UK); 1:1,000 for keratin 6 (Covance, Princeton, NJ). Sections were
counterstained with hematoxylin and mounted.
Double immunoﬂuorescence analysis of Ki67 (Novocastra Labora-
tories, Newcastle upon Tyne, UK) and laminin γ1 (Millipore, Danvers,
MA) was performed on paraformaldehyde-ﬁxed, frozen sections of
tissue embedded in OCT (Sakura Finetek, Torrance, CA). Both primary
antibodies were applied at 1:1,000, and signals were detected using
Alexa 488-conjugated anti-rabbit and Alexa 594-conjugated anti-rat,
respectively, with Hoechst 33258 as a counterstain. The number of
Ki67-positive suprabasal cells present in a ﬁeld encompassing 100
Ki67-positive basal cells was used as ameasurement of suprabasal cell
hyperproliferation (Hansen et al., 2000). A total of at least 100 Ki67-
positive basal cells were counted in each sample. Proliferation of basal
cells was assayed by determining the percentage of Ki67-positive cells
in the basal layer in a population of at least 100 Hoechst 33258-
positive basal cells for each sample.
In situ hybridization
Embryos at various stages were ﬁxed and parafﬁn-embedded as
described above, except that the ﬁxation was performed at 4 °C
overnight. In situ hybridization with digoxigenin-UTP labeled ribop-
robes was performed as described (Moulson et al., 2007), with
hybridization temperatures ranging from 55 to 60 °C.
Riboprobes were synthesized from either linearized plasmids or
PCR amplicons using DIG RNA labeling mix (Roche, Mannheim,
Germany) and RNA polymerase Plus (Ambion, Austin, TX), and
puriﬁed by NucAway spin columns (Ambion) following the manu-
facturers' instructions. For some of the genes examined, both anti-
sense and sense riboprobes were tested on samples to conﬁrm their
speciﬁcities. The plasmids contained cDNAs from: Areg (clone ID
3597695), Ereg (clone ID 5325124), Epgn (clone ID 8734042), Mmp3
(clone ID 3962288), Ccl12 (clone ID 1548072), Iﬁ202b (clone ID
4945974; all above are IMAGE clones obtained from OpenBiosystesm,
Huntsville, AL), and Il24 (clone IDRZPDp981C12223D; from imaGenes,
Berlin, Germany). The PCR amplicons were generated using the cDNAs
reverse-transcribed from RNA with Superscript III reverse transcrip-
tase (Invitrogen). Primers used to make PCR amplicons were as
follows, with T7 and T3 promoter sequence underlined: Klk7: 5′
TATAATACGACTCACTATAGGGGAGTGCAAGAAGGTGTACAAG 3′ and 5′
GAAATTAACCCTCACTAAAGGGTGGAGGAAAGGTAAAGCCAG3′,Dusp6:
5′ TATAATACGACTCACTATAGGGGGATCACTGGAGCCAAAAC 3′ and 5′
GAAATTAACCCTCACTAAAGGGGGAACTGAAGGAATGGGGAC 3′.
RNA isolation and microarray analyses
Total RNAs were isolated from the dorsal skin of embryos at E15.5
using a tissue homogenizer (Powergen 125, Fisher Scientiﬁc,
Pittsburgh, PA) and the RNeasy Fibrous Tissue Mini kit with an in-
column DNase treatment (Qiagen, Chatsworth, CA) following the
manufacturer's instructions. Puriﬁed RNAs were qualitatively
assessed by RNA LabChip (Agilent, Palo Alto, CA) and quantiﬁed
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gies, Wilmington, DE). To make analytical duplicates, equal amounts
of two RNA samples of the same genotype were pooled and split into
two tubes. The preparation of biotin-labeled, antisense cRNA targets
and microarray hybridization were performed in the Siteman Cancer
Center Multiplexed Gene Analysis Core using standard protocols
supplied by the manufacturer (Affymetrix, Santa Clara, CA). Double-
stranded cDNAs were generated from 5 µg of total RNA with T7-T24
primers (Genset, Paris, France), Superscript II reverse transcriptase,
Escherichia coli ligase, and E. coli polymerase I (Invitrogen, Carlsbad,
CA). Biotin-labeled, antisense cRNA targets were generated from the
synthesized cDNAs using the Enzo BioArray High Yield RNA Transcript
Labeling kit (Enzo Biochemical, New York, NY). Ten micrograms of
each biotinylated cRNA preparation were fragmented and hybridized
to themouse genome arrayMOE430A2 for 16 h in Hybridization Oven
640. Microarrays were then washed in Fluidics Station using the
standard “Eukaryotic GE Wash 2” protocol followed by signal
detectionwith antibody-mediated signal ampliﬁcation. The processed
arrays were scanned by GeneChip Scanner 3000 to generate image
ﬁles (.dat ﬁles) and cell intensity ﬁles (.cel ﬁles).
Analyses of microarray data
Scanned images were processed using AffymetrixMicroarray Suite
(MAS 5.0) and exported as text ﬁles containing both qualitative and
quantitative analyses for each probe set. Cell intensity ﬁles were
normalized based on total intensity using affy package (RMAmethod)
from BioConductor (http://www.bioconductor.org/, Biostatistics
Unit of Dana Farber Cancer Institute, Harvard Medical School) and
exported as text ﬁles for numerical analyses. Fatp4 mutant embryos
(experimental samples as the numerator) were compared to their
heterozygous littermates (control samples as the denominator). Data
from analytical duplicates were analyzed statistically by R multtest
package (Resampling-based multiple hypothesis testing, BioConduc-
tor), and those with adjusted P-value less than 0.05 were selected. To
ﬁlter false positives, data with increased fold changes but with absent
calls in the experimental samples were eliminated. Likewise, data
with decreased fold changes but with absent calls in the control
samples were also eliminated. A cut-off value of 1.5-fold change was
used to identify genes that showed the most signiﬁcant variation in
expression. To biologically annotate genes that showed differential
expression, GenMAPP was applied to grouping genes along Gene-
Ontology (GO) categories or biological pathways (http://www.
genmapp.org/, Gladstone Institutes, University of California at San
Francisco) (Doniger et al., 2003). Signiﬁcance of differential gene
expression in a speciﬁc GOwas determined by Z scores, an indicator to
show whether in a speciﬁc GO, there was a difference in the ratio of
genes changed as compared to the background ratio in the entire GO.
A positive Z score indicates there are more genes changed in a GO
term than would be expected by random chance, and vice versa.
RT-quantitative PCR (RT-qPCR)
Total RNAs were isolated from E15.5 dorsal skin or from E16.5
dorsal skin epidermis as described above. To isolate the epidermis, the
dorsal skin was incubated in dispase II (5 mg/ml; Roche) at 4 °C for
4 h, and the epidermis was peeled from the skin. Complementary DNA
(cDNA) was generated from 0.2 µg of total RNA using Superscript III
reverse transcriptase with oligo(dT)12–18 (Invitrogen) in a 30-µl
reaction incubated at 50 °C for 1 h. Real-time PCR ampliﬁcation was
performed in triplicate using the fast mode (annealing and extending
at 60 °C) of the 7900 HT Fast Real-Time PCR system (Applied
Biosystems, Foster City, CA). Each replicate contained cDNA tran-
scribed from 3 ng of RNA, a primer pair at optimized concentration
(100 or 30 nM), and Fast SYBR Green Master Mix in a 10 µl reaction
(Applied Biosystems). In triplicates with a standard deviation greaterthan 0.3, the outlier Ct was excluded. The comparative Ct (threshold
cycle) method (2-ΔCt) was used for relative quantiﬁcation of gene
expression (Livak and Schmittgen, 2001; Schmittgen and Livak,
2008), with Tbp as a reference gene (Minner and Poumay, 2009). To
validate the comparative Ct method (Bustin et al., 2009), cDNA
derived from 1 µg of total RNA in a 30 µl RT reaction was ﬁve-fold
serially diluted over a 3 log10 range and subjected to real-time PCR
with all primer pairs. The ampliﬁcation efﬁciency (Ex) of each primer
pair was calculated as described by the manufacturer from the slope
of its linear regression line of Ct versus log10 cDNA concentrations
using the equation Ex=10(-1/slope)-1, with Ct larger than 35 excluded
from the calculation. Except for Il24, Cst6, and Junb, whose expression
levels were too low to be assayed in a 3 order of magnitude range, all
target genes showed Ex values similar to the reference gene Tbp
(within a range of ±10%), with close correlation among dilutions
(squared correlation coefﬁcients R2N0.99). Genomic DNA contami-
nation was veriﬁed to be minimal for all target genes of interest using
RT reactions without reverse transcriptase.
Most primer pairs were designed to anneal either to the 3'
untranslated region or to different exons of genes using Primer Express
(Applied Biosystems). The speciﬁcity of each primer was veriﬁed by
BLAST screen against the mouse genome and transcript database, by a
distinct single peak during the dissociation curve analysis, and by a
single band of the expected size on an electrophoretic gel. The primer
sequences used are listed in Supplementary Table 1.
Tyrphostin AG1478 and Curcumin treatment
Tyrphostin AG1478 (purityN99%; LC laboratories, Woburn, MA)
was prepared as a 160 mM working solution in DMSO and stored at
-20 °C. Curcumin (purityN80%; Sigma-Aldrich, St. Louis, MO) was
prepared freshly as a 50-mM working solution in DMSO. Pregnant
females at 14.5 days of gestation were injected i.p. in the morning for
2 days with AG1478, curcumin, or vehicle only at 100 µl per 35 g of
body weight. Embryos were then removed at E16.5.
Statistical analysis
Two-tailed, unpaired Student's t-tests were used to determine
statistical difference in TEWL and hyperproliferation assays. Two-way
mixed model ANOVA tests were used to evaluate statistical difference
in gene expression assays by RT-qPCR. Differences were considered
signiﬁcant when the P value was b0.05.
Results
Epidermal hyperproliferation in Fatp4 mutants
Fatp4−/− embryos display epidermal hyperplasia and hyperker-
atosis from E15.5 onwards. At E15.5, when the corniﬁed layer in
control animals is barely visible, mutants already possess a distinct
corniﬁed layer. Moreover, expression of keratin 6 inmutant epidermis
indicates an altered proliferation or differentiation program (Moulson
et al., 2003). To directly examine whether the epidermal hyperplasia
was associated with hyperproliferation of keratinocytes, the skin of
Fatp4 mutant embryos was analyzed for Ki67 immunoreactivity to
identify proliferating cells. From E15.5 onwards, mutant embryos
exhibited many more Ki67-positive cells in the suprabasal layers
compared to controls (E16.5 shown in Fig. 1A, B). For example, at
E16.5 Fatp4 mutant embryos displayed 2.6 fold as many proliferating
cells as did controls (Pb0.01; Fig. 1C). A signiﬁcant increase in
suprabasal proliferating cells was also observed in Fatp4 mutants as
late as E18.5 (data not shown). These results show that the epidermal
hyperplasia of Fatp4 mutants is associated with an increased number
of suprabasal proliferating cells.
Fig. 1. Epidermal hyperplasia in Fatp4mutants is associated with hyperproliferation of suprabasal keratinocytes. (A and B) Dorsal skin sections from E16.5 Fatp4−/− (B) and control
littermates (A) were subjected to double immunoﬂuorescence analyses for Ki67 (green) and laminin γ1 (red). Laminin γ1 demarcates the dermo-epidermal boundary. Mutants
exhibited an increased number of Ki67-positive cells (arrowheads) in the suprabasal layer compared to controls. Hair follicle progenitors are indicated by the asterisk. Scale bar is
100 μm. (C) Fatp4mutants at E16.5 showed 2.6 times as many Ki67-positive suprabasal cells as did controls (51.7±4.5, n=3mutants, vs. 20.0±5.6, n=3 controls; Pb0.01). The Y
axis indicates numbers of Ki67-positive suprabasal cells per 100 Ki67-positive basal cells. Error bars indicate standard deviation.
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We previously reported that Fatp4mutants exhibit a defective skin
barrier at late fetal stages, as assayed by inward permeability of X-Gal
at low pH (Moulson et al., 2003). Because the epidermal hyperpro-
liferation was observed from E15.5 onwards, when embryos are still
in the uterus and not challenged by the postnatal environment, it is
unlikely that the hyperproliferation shown above is a compensatory
response to a defective skin barrier in the manner shown previously
(Proksch et al., 1991). To investigate the barrier defect in more detail,
we reexamined it at multiple stages. At E17.5, barrier formation was
complete in control embryos but incomplete in Fatp4 mutants, as
indicated by staining of the body wall (Fig. 2C). At E15.5, neither
controls nor Fatp4 mutants manifested a skin barrier (Fig. 2A). AtFig. 2. Abnormal skin barrier formation in Fatp4mutants. Embryos at E15.5 to E17.5were tested
both controls andmutantswere permeable to X-Gal, as indicated by the blue staining throughou
while Fatp4mutants had already formed a substantial skin barrier throughout the body wall. (
Fatp4tg/+ fetuses displayed a remedied barrier, comparable to that of normal Fatp4+/− embr
mutants carrying a hemizygous X-linked Ivl-Fatp4 transgene (lower panel). Each caliber in A-C
(108.2±9.9 g/m2h, n=2 vs. 105.5±3.8 g/m2h, n=5; PN0.05). At E16.5 Fatp4mutants displa
n=11; *Pb0.05), indicating premature barrier establishment. However, the premature barrier
n=3mutants vs. 13.4±3.3 g/m2h, n=3 controls; **Pb0.01).E16.5, some of the controls had just begun to establish a barrier
dorsally, but the Fatp4 mutants had already established a substantial
but imperfect skin barrier throughout the body wall (Fig. 2B),
comparable to that observed in E17.5 mutants (compare to Fig. 2C).
This premature barrier formation in Fatp4mutants was conﬁrmed by
an alternative skin permeability assay using toluidine blue (data not
shown). The precocious barrier did not, however, progress into a
complete barrier at later stages. It remains to be determined whether
premature barrier formation exhibits the typical dorsal to ventral
wave.
In addition to abnormalities in inward permeability of the skin,
Fatp4 mutants also showed defects in outward transepidermal water
loss (TEWL) from E16.5 onwards (Fig. 2D). At E15.5, Fatp4 mutants
showed little difference in TEWL compared to controls (PN0.05). Infor barrier integrity by (A–C) X-Gal permeability assays and (D) TEWL assays. (A) At E15.5
t the bodywall. (B) At E16.5 the controls had just begun to establish a skin barrier dorsally,
C) Whereas Fatp4mutants showed incomplete barrier formation at E17.5, Fatp4−/−; Ivl-
yos (upper panel). The barrier defect at E17.5 was only partially rescued in female Fatp4
is 1 mm. (D) At E15.5 Fatp4mutants showed little change in TEWL compared to controls
yed reduced TEWL compared to controls (33.4±10.8 g/m2h, n=3 vs. 75.7±3.9 g/m2h,
did not progress to completion by E17.5,when control skin had done so (24.5±1.4 g/m2h,
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water evaporation rate compared to control littermates (*Pb0.05),
indicating premature skin barrier formation. However, the premature
barrier of Fatp4 mutants did not progress into a complete barrier by
E17.5, when control embryos had formed one (**Pb0.01).
We have shown that transgenic expression of FATP4 in Fatp4
mutant epidermis using the involucrin (Ivl) promoter rescues the
neonatal lethality and ameliorates the skin phenotypes (Moulson
et al., 2007); here we show that an effective barrier was established in
Fatp4−/−; Ivl-Fatp4tg/+ mice carrying an autosomal Ivl-Fatp4 trans-
gene (upper panel in Fig. 2C). In contrast, the abnormalities in barrier
formation were only partially rescued in female Fatp4 mutants
carrying a hemizygous X-linked Ivl-Fatp4 transgene (lower panel in
Fig. 2C), which is consistent with a mosaic pattern of transgene
expression due to random X-inactivation in females. Together, these
studies show crucial, skin-intrinsic roles for FATP4 in the development
of skin.
Gene expression analysis of Fatp4 mutant skin
To identify the possible mechanisms accounting for the abnormal
development of skin and its appendages in Fatp4mutants, we carried
out microarray analyses with skin RNAs from E15.5 Fatp4+/− and
Fatp4−/− embryos. E15.5 was chosen because it is the age at which
the skin phenotype ﬁrst becomes apparent, increasing the likelihood
that observed changes in gene expression would be causative of,
rather than a result of, the phenotype. Total skin RNAs were isolated
and hybridized in analytical duplicates to Affymetrix oligonucleotide
microarrays. Both statistical and nonstatistical criteria were applied to
ﬁlter the array data, as described in Materials and methods. In
comparisons of Fatp4 mutant samples to heterozygous littermates,
531 and 213 probe sets were found to show at least a 1.5-fold increase
or decrease in expression, respectively. Out of those probe sets, 338
and 148 genes, respectively, were mapped to Gene-Ontology (GO)
terms (supplementary Tables 2 and 3).
Table 1 lists a subset of genes that showed differential expression
in Fatp4mutants. Given the impact of FATP4 loss on proliferation and
differentiation in the epidermis, we focused our analysis on gene
classes known to be involved in regulating the formation of skin and
its appendages. Genes encoding EGF family ligands and signal
transducer and activator of transcription 3 (STAT3) were signiﬁcantly
upregulated, alongwith genes regulating cell proliferation, such as the
Myc, Fos, Jun, and Junb oncogenes. Additionally, there was signiﬁcant
upregulation of the genes encoding proteins involved in keratinocyte
differentiation and barrier formation, such as Ivl, small proline-rich
proteins (Sprr's), and S100 calcium binding proteins (S100a’s). This
pattern is consistent with the premature barrier formation observed
in Fatp4 mutants (Fig. 2).
Ectopic activation of EGFR signaling in Fatp4 mutant epidermis
To further investigate the expression of a subset of candidate genes
identiﬁed in the arrays, RT-quantitative PCR (qPCR) was performed
for relative quantiﬁcation of gene expression using TATA box binding
protein (Tbp) as an internal control (Minner and Poumay, 2009). Of
the 26 genes tested, all except transforming growth factor alpha
(Tgfa) were found to be differentially expressed in Fatp4 mutants
compared to controls (Table 1). One group of veriﬁed genes encodes
proteases, including kallikrein 7 (KLK7), a serine protease involved in
desquamation (Komatsu et al., 2003), and matrix metalloproteinase 3
(MMP3); their upregulation was also conﬁrmed by in situ hybridiza-
tion (Fig. 3E–H). Another group of genes veriﬁed by RT-qPCR encodes
EGF family ligands involved in the regulation of keratinocyte
functions: amphiregulin (Areg), epiregulin (Ereg), and epithelial
mitogen/epigen (Epgn). These three genes are clustered within
110 kb on mouse chromosome 5 (Harris et al., 2003). By in situhybridization Epgn transcripts were found throughout the epidermis
in Fatp4 mutants, whereas no expression was detected in controls
(Fig. 3A, B). Upregulation of Areg and Eregwas also validated by in situ
hybridization (data not shown). Concomitant with this, Fatp4mutants
displayed ectopic suprabasal activation of the EGFR, indicated by the
expanded domain of phosphorylated EGFR (pEGFR), from E15.5
onwards (Figs. 4A, B and 5M, N). Suprabasal pEGFR localization is an
indicator of epidermal hyperproliferation (Fuchs and Raghavan, 2002;
Weiss et al., 1984).
EGFR signaling can be exerted through multiple downstream
pathways, including MAPK superfamily cascades (ERK, JNK, p38), the
PI3K/Akt pathway (Dent et al., 2003), and the STAT3 pathway
(Buettner et al., 2002). For example, Ras/ERK-mediated EGFR
signaling can regulate cell growth and transformation (Howe et al.,
1992). Although Fatp4mutants exhibited ectopic activation of EGFR in
suprabasal keratinocytes, they showed reduced activation of ERK in
the epidermis at E15.5 (supplementary Fig. 1). Because ERK activity
reﬂects the opposing actions of upstream activator kinases (MEK) and
inhibitoryMAPK phosphatases, reduced ERK activity could result from
the observed induction of its inhibitory phosphatase Dusp6, shown by
RT-qPCR (Table 1) and in situ hybridization (Fig. 3I, J). Activation of
p38 MAPK was not altered in Fatp4mutant epidermis, as detected by
immunostaining for phospho-p38 (supplementary Fig. 1). In contrast,
activation of JNK appeared reduced in Fatp4 mutant epidermis, as
determined by immunostaining for phospho-JNK (supplementary
Fig. 1). It is not clear whether the reduction in JNK activation is related
to the skin abnormalities in Fatp4mutants. Nevertheless, these results
suggest that the ectopic EGFR signaling was not exerted via activation
of MAPK superfamily cascades, but rather via activation of other
pathways.
Activation of STAT3 signaling in Fatp4 mutant epidermis
STAT3 is a signaling molecule activated by both cytokines and
growth factors, and STAT3 activation is required for EGFR-mediated
cell growth in vitro (e.g., Grandis et al., 1998) and in vivo (Chan et al.,
2004). Activation of STAT3 involves phosphorylation by receptor
tyrosine kinases or Janus kinases (JAKs), dimerization, and transloca-
tion into nuclei, where it serves as a transcription factor to drive
expression of downstream target genes (Buettner et al., 2002). Stat3
mRNA was modestly upregulated in Fatp4 mutants (Table 1), but to
examine whether the observed ectopic EGFR signaling (Figs. 4A, B and
5M, N) correlated with ectopic STAT3 activation, skin samples were
subjected to immunohistochemical analyses. At E14.5, phosphorylat-
ed STAT3 (pSTAT3) was neither detected in controls nor in Fatp4
mutants (Fig. 4G, H). At E15.5, however, Fatp4 mutants showed
distinct signals in the nuclei of basal and suprabasal keratinocytes
(Fig. 4F), indicating STAT3 activation. Activation of STAT3 signaling in
the mutant epidermis continued at E16.5 (Fig. 4D) and was evident at
least through E18.5 (data not shown). These data suggest that STAT3
signaling could be an effector of the ectopic EGFR activation, and
perhaps other signaling pathways, in Fatp4 mutants.
Besides receptor tyrosine kinases such as EGFR, cytokine receptors
are the other major initiators of STAT signaling. As cytokine receptors
lack intrinsic tyrosine kinase activity, cytokine-induced activation of
STAT is mediated by receptor-associated tyrosine kinases such as JAK2
(Buettner et al., 2002). Interestingly, Fatp4 mutants exhibited ectopic
activation of JAK2 in suprabasal layers (Fig. 5R). Furthermore, the
array data showed a robust immune response signature in Fatp4
mutants (Table S1). Many cytokines have been found to be expressed
in keratinocytes, either constitutively or in pathological states (Grone,
2002). Upregulation of several cytokines in the Fatp4mutant skin was
veriﬁed by RT-qPCR and in situ hybridization. For example, whereas
Il24 expression was not detectable by RT-qPCR in four of the ﬁve
control embryos examined, it was induced in all six mutants (Table 1).
Induction of Il24 was also validated by in situ hybridization (data not
Table 1
Genes changed in the skin at E15.5 in Fatp4−/− embryos, compared to controls.
GenBank accession Gene symbol Gene name Fold change by arrays^ Fold change by RT-qPCR#
Immune response
U50712 Ccl12 chemokine (C-C motif) ligand 12 7.3 6.1***
NM_011940 Iﬁ202b interferon activated gene 202B 10.4 8.3***
AF333251 Il24 interleukin 24 4.7 ↑
NM_011019 Osmr oncostatin M receptor 5.1 2.6**
NM_021367 Tslp thymic stromal lymphopoietin 14.6
Signal transduction
NM_009704 Areg amphiregulin 4.1 11.2***
AV239587 Bmp2 bone morphogenetic protein 2 -1.6
NM_053087 Epgn epithelial mitogen 44.6 30.9***
NM_007950 Ereg epiregulin 9.0 3.3**
AU023352 Jak2 Janus kinase 2 1.8
BB241535 Socs3 suppressor of cytokine signaling 3 9.8 2.9**
AI325183 Stat3 signal transducer and activator of transcription 3 2.1 1.8**
U65016 Tgfa transforming growth factor alpha 3.9 1.1
Transcription
AV231755 hr hairless 3.7 2.6**
NM_010703 Lef1 lymphoid enhancer binding factor 1 -2.3 -2.1**
Cell proliferation
AV026617 Fos FBJ osteosarcoma oncogene 1.6
NM_010235 Fosl1 fos-like antigen 1 4.4 19.8***
NM_010591 Jun Jun oncogene 1.9
NM_008416 Junb Jun-B oncogene 7.3 7.0***
BC006728 Myc myelocytomatosis oncogene 1.5 1.6**
AI462015 Nfkbia nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha 2.0
NM_018754 Sfn stratiﬁn 2.1
Cell adhesion
BC008626 Icam1 intercellular adhesion molecule 3.4 2.2***
L04678 Itgb4 integrin beta 4 1.7
Keratinocyte differentiation
NM_008412 Ivl involucrin 20.9
NM_011313 S100a6 S100 calcium binding protein A6 (calcyclin) 1.6
NM_013650 S100a8 S100 calcium binding protein A8 (calgranulin A) 9.2 8.0**
NM_009114 S100a9 S100 calcium binding protein A9 (calgranulin B) 21.4 23.5***
NM_009264 Sprr1a small proline-rich protein 1A 9.9 10.7***
NM_009265 Sprr1b small proline-rich protein 1B 18.7
NM_011468 Sprr2a small proline-rich protein 2A 20.2
NM_011470 Sprr2d small proline-rich protein 2D 19.4
NM_011472 Sprr2f small proline-rich protein 2F 8.1
BC026422 Tgm1 transglutaminase 1, K polypeptide 2.4
Protein modiﬁcation
NM_026268 Dusp6 dual speciﬁcity phosphatase 6 3.5 2.6***
BE136125 Dusp7 dual speciﬁcity phosphatase 7 3.0
BB261602 Map2k6 mitogen activated protein kinase kinase 6 -2.0
Intermediate ﬁlament cytoskeleton
NM_008470 Krt16 (Krt1-16) keratin 16 (keratin complex 1, acidic, gene 16) 70.2
AA798563 Krt17 (Krt1-17) keratin 17 (keratin complex 1, acidic, gene 17) 8.3
NM_008476 Krt6a (Krt2-6a) keratin 6A (keratin complex 2, basic, gene 6a) 4.5
NM_010669 Krt6b (Krt2-6 g) keratin 6B (keratin complex 2, basic, gene 6 g) 166.9
Intercellular junction
AV239646 Gjb2 gap junction membrane channel protein beta 2 3.9 3.0*
Peptidase activity
NM_007403 Adam8 a disintegrin and metallopeptidase domain 8 5.4 6.6***
NM_011177 Klk6 (Prss18) kallikrein related-peptidase 6 (protease, serine, 18) 12.0
BB283507 Klk7 kallikrein related-peptidase 7 20.7 64.2***
NM_010809 Mmp3 matrix metalloproteinase 3 20.1 39.0***
Peptidase inhibitor activity
NM_011111 Serpinb2 serine (or cysteine) proteinase inhibitor, clade B, member 2 7.8 5.4***
AK003744 Cst6 cystatin E/M 9.9 8.3***
^Data indicate gene expression changes in Fatp4 mutant compared to control skin by array analyses in analytical duplicates, as described in Materials and methods.
#26 genes were tested by RT-qPCR, using RNA from three separate litters (5 controls and 6 Fatp4mutants) different from those used for the arrays. Gene expression was quantiﬁed as
described in Materials and methods and analyzed by two-way mixed model ANOVA tests. Changes in 25 of the 26 genes were veriﬁed, and all except Il24 are indicated with fold
change and statistical signiﬁcance (*Pb0.05; **Pb0.01; ***Pb0.001).
↑The fold change and statistical signiﬁcance of Il24 upregulation were unable to be determined because expression of Il24was undetectable in four out of the ﬁve control RNAs assayed.
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Iﬁ202b, a gene induced by interferons in autoimmune patients
(Mondini et al., 2007), was detected in Fatp4 mutants by RT-qPCR
(Table 1) and by in situ hybridization (Fig. 3C, D and data not shown).
Upregulation of Tslp, encoding thymic stromal lymphopoietin, has
been previously veriﬁed in Fatp4mutants by the presence of elevated
serum TSLP levels at birth (Demehri et al., 2008). These results suggest
that in addition to EGFR-mediated activation, cytokine-mediatedSTAT3 activation could also account for the skin abnormalities in Fatp4
mutants.
Inhibition of EGFR/STAT3 activation suppresses hyperproliferation
To investigate whether EGFR activation was related mechanisti-
cally to the skin abnormalities of Fatp4 mutants, we inhibited EGFR
activation using Tyrphostin AG1478, an EGFR-speciﬁc tyrosine kinase
Fig. 4. Activation of EGFR and STAT3 in Fatp4 mutant skin. Dorsal skin sections from
Fatp4+/− and Fatp4−/− littermates at the indicated ages were analyzed by
immunohistochemistry with antibodies against pEGFR (A and B) or pSTAT3 (C to H;
counterstained with hematoxylin). (A and B) Whereas pEGFR signals were detected
only in basal keratinocytes in controls, ectopic signals were detected in suprabasal
keratinocytes in mutants. (C-H) At E15.5 and E16.5, only mutants showed distinct
nuclear pSTAT3 signals in basal and suprabasal layers. At E14.5, neither controls nor
mutants showed epidermal pSTAT3 signals. Hair follicle progenitors are indicated by
asterisks. Dashed lines demarcate the dermo-epidermal boundary. Scale bar is 50 μm.
Fig. 3. Abnormal geneexpression in Fatp4mutant skin. Dorsal skin sections from Fatp4−/−
and control littermates at E16.5 were subjected to in situ hybridization with the indicated
riboprobes. Sections A to Hwere counterstainedwith nuclear fast red. (A and B) Epgnwas
ectopically expressed throughout the epidermis inmutants at E16.5. (C andD) Iﬁ202bwas
ectopically activated in mutants in interfollicular epidermis but was detected only in hair
placodes in controls (asterisk in C). (E and F) Klk7was induced in the granular and upper
spinous layers inmutants. (GandH) Induction ofMmp3 inmutantswas detectedmostly in
the basal layer. (I and J) Dusp6was induced in mutants in interfollicular epidermis (J) but
was expressed only in hair follicle progenitors in controls (asterisks in I). Dashed lines
demarcate the dermo-epidermal boundary. Hair follicle progenitors are indicated by
asterisks. Scale bar is 50 μm.
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abnormalities in Fatp4 mutants were not observed until E15.5,
pregnant females were injected with AG1478 solubilized in DMSO
orwith DMSO only at E14.5 and E15.5 and then sacriﬁced at E16.5. The
epidermal hyperplasia normally observed in Fatp4 mutants was
suppressed by AG1478 but not by vehicle (DMSO) (compare Fig. 5B to
D); the ﬂat skin and sparse hair phenotypes, however, were not
remedied. AG1478 treatment did not appear to adversely affect
control littermates (compare Fig. 5A to C).
To correlate suppression of epidermal hyperplasia with suppres-
sion of EGFR and perhaps also STAT3 activation, immunohistochem-
ical analyses were performed. Upon AG1478 treatment, both
suprabasal activation of EGFR and nuclear localization of pSTAT3
were dramatically reduced in Fatp4mutant skin, compared to vehicle
treatment. For example, nuclear pSTAT3 was detected in about 25% of
the epidermal cells in the AG1478-treated mutant skin, compared to
about 50% in the vehicle-treated mutant skin (compare Fig. 5F to H).
Similarly, the AG1478-treated mutants showed only a few pEGFR-positive cells in the spinous layer, whereas the vehicle-treated
mutants showed positive cells throughout the spinous layer (compare
Fig. 5N to P), as observed with no treatment (Fig. 4B). AG1478
treatment also dramatically reduced the expression of K6 in Fatp4
mutants (compare Fig. 5J to L). We next examined whether the
attenuation of STAT3 signaling was correlated with suppressed
activation of JAK2, a molecule involved in both EGFR-mediated and
cytokine-mediated STAT3 activation. With AG1478 treatment, the
activation of JAK2 in the suprabasal layer was signiﬁcantly reduced as
compared to mutants treated with DMSO (compare Fig. 5R to T),
suggesting that inhibition of EGFR signaling is sufﬁcient to block JAK2
activation regardless of the presence of cytokines. Alternatively,
administration of AG1478 may inhibit JAK2 activation by suppressing
cytokine expression.
To provide evidence that the effects of AG1478 were not
nonspeciﬁc, we inhibited EGFR and STAT3 activation in a completely
different fashion, using curcumin. Curcumin is an Indian spice isolated
from the turmeric plant that is a documented inhibitor of STAT3
activation; it suppresses both phosphorylation and nuclear translo-
cation of STAT3 (Bharti et al., 2003). It also inhibits phosphorylation of
EGFR (Korutla and Kumar, 1994) and JAK2 (Natarajan and Bright,
2002) and inhibits the tyrosine kinase activities of the EGFR (Korutla
and Kumar, 1994) and Src (Reddy and Aggarwal, 1994), both of which
can phosphorylate STAT3. Indeed, the epidermal hyperplasia of Fatp4
mutants was suppressed by curcumin, accompanied by a dramatic
reduction of nuclear pSTAT3 (compare Fig. 6B to D, F to H). In contrast
to AG1478, curcumin only moderately reduced the ectopic activation
of EGFR and JAK2 in the suprabasal layer of mutants (compare Fig. 6N
Fig. 5. AG1478 treatment suppresses STAT3 activation and epidermal hyperplasia. Embryos were dissected at E16.5 from pregnant females injected i.p. with AG1478 or DMSO
vehicle daily for 2 days. Dorsal skin sections of Fatp4−/− and control littermates were then subjected to hematoxylin and eosin staining (A–D) and immunohistochemical
analyses (E–T). Some sections were counterstained with hematoxylin (E–L). (A–D) AG1478 treatment suppressed the thickened epidermis phenotype (compare white brackets
in B and D) but not the ﬂat skin phenotype (compare C to D). (E–H)Nuclear localization of pSTAT3 inmutantswas dramatically reduced by AG1478 (compare F to H; arrowhead in
Hmarks residual nuclear signal). (I–L) AG1478 treatment dramatically reduced the ectopic expression of keratin 6 (compare J to L), which is normally expressed only in periderm
(arrowhead in I). (M–P) Ectopic activation of the EGFR in the suprabasal layer ofmutants was greatly reduced by AG1478 (compare N to P). (Q–T) AG1478 treatment also reduced
ectopic JAK2 activation in mutant suprabasal layers (arrowhead in R; compare R to T). Note the pEGFR and pJAK2 signals in dermal blood vessels in both controls and mutants.
Dashed lines demarcate the dermo-epidermal boundary. Hair follicle progenitors are indicated by asterisks. Scale bar is 50 μm.
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hair phenotypes were not ameliorated by curcumin. Taken together,
these results suggest that hyperplasia in Fatp4mutants is mediated by
EGFR/STAT3 activation.
In addition to suppression of hyperplasia, administration of
AG1478 (Fig. 7A) and curcumin (data not shown) also inhibited
precocious barrier formation in Fatp4 mutants. At E16.5 the vehicle-
treated mutants displayed a widespread precocious skin barrier,
whereas AG1478-treatedmutants had acquired only a slight barrier in
the dorso-lateral region (arrowheads in Fig. 7A). Nevertheless,
AG1478 treatment did not remedy the incomplete skin barrier
observed in mutants from E17.5 onwards (data not shown; curcumin
has not been tested in this context). These results suggest that the
precocious barrier formation in Fatp4 mutants is due to increased
EGFR/STAT3 activation.
To determine whether the AG1478-mediated reduction of epider-
mal hyperplasia was due to prevention of suprabasal keratinocytehyperproliferation, the skin of vehicle- and drug-treated embryos was
analyzed for Ki67 immunoreactivity to identify proliferating cells
(Fig. 7B, C). Upon DMSO treatment, Fatp4 mutant skin displayed 2.9
times as many proliferating cells in the suprabasal layer as did control
skin (52.5±22.1, n=4mutants vs. 18.0±5.8, n=4 controls; Pb0.05)
(Fig. 7C), similar to the results with no treatment (Fig. 1C). In contrast,
upon AG1478 treatment, Fatp4 mutant skin displayed only 1.5 times
as many proliferating cells in the suprabasal layer vs. control (32.3±
7.3, n=4 mutants vs. 21.0±2.9, n=4 controls), a more modest but
still statistically signiﬁcant difference (Pb0.05) (Fig. 7C). Neverthe-
less, the AG1478-mediated reduction in the proliferation increase
observed in mutants (the 1.5- vs. 2.9-fold increase in proliferation
over controls) was signiﬁcant (Pb0.01) (Fig. 7C). The AG1478-
mediated remedy of suprabasal cell hyperproliferation was not
associated with a reduction of proliferation in the basal layer, as
DMSO- and AG1478-treated mutant epidermis showed similar
proliferation in the basal layer (99%, PN0.05).
Fig. 6. Curcumin treatment suppresses STAT3 activation and epidermal hyperplasia. E16.5 embryos were dissected from pregnant females injected i.p. with curcumin or vehicle daily
for 2 days. Dorsal skin sections from Fatp4−/− and control littermates were then subjected to hematoxylin and eosin staining (A–D) or immunohistochemical analyses (E–T). Some
sections were counterstained with hematoxylin (E–L). (A–D) Curcumin treatment suppressed the thickened epidermis phenotype (compare white brackets in B and D) but not the
ﬂat skin phenotype (compare C to D). (E–H) Nuclear localization of pSTAT3 was dramatically reduced by curcumin (compare F to H; arrowheads in Hmark residual nuclear signals).
(I–L) Curcumin treatment drastically reduced the ectopic activation of keratin 6 (compare J to L). (M–P) Ectopic EGFR activation in mutant suprabasal cells was moderately
suppressed by curcumin (compare N to P). (Q–T) Curcumin treatment also moderately reduced ectopic JAK2 activation in mutant suprabasal layers (arrowheads in R; compare R to
T). Dashed lines demarcate the dermo-epidermal boundary. Hair follicle progenitors are indicated by asterisks. Scale bar is 50 μm.
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FATP4 and epidermal hyperproliferation
Newborn mice lacking FATP4 display a dramatically thickened,
ﬂat epidermis aswell as a defective skin barrier. Herewe investigated
the cellular and molecular mechanisms for the epidermal hyperpla-
sia and barrier defects and made several important observations.
(1) The epidermal hyperplasia manifested by Fatp4 mutants was
associated with an increased number of proliferating cells in the
suprabasal layer of the epidermis. (2) Expression of three EGF family
ligands (Areg, Ereg, and Epgn) was increased in Fatp4 mutant
epidermis. (3) Phosphorylation of the EGF receptor, an indicator of
EGFR activation, was detected ectopically in Fatp4mutant suprabasal
layers. (4) Nuclear localization of phosphorylated STAT3, a down-
stream effector of EGFR signaling, was detected suprabasally in the
mutant but not in the control epidermis. (5) Pharmacological
inhibition of EGFR tyrosine kinase activity partially suppressedphospho-STAT3 nuclear translocation, suprabasal keratinocyte pro-
liferation, skin thickening, and precocious skin barrier formation.
Together, these ﬁndings strongly suggest that the absence of FATP4
during the early stages of skin development leads to an upregulation
of the expression of EGF family ligands, and this sets into motion the
events described above, leading to epidermal hyperproliferation and
skin thickening. The mechanisms whereby the lack of FATP4 causes
changes in expression of EGF family member genes remain to be
determined.
Involvement of EGFR and STAT3 activation in the epidermis
EGFR signaling functions in diverse aspects of skin biology and
pathology, including keratinocyte proliferation, hair follicle morpho-
genesis, wound healing, psoriasis, and tumorigenesis (Schneider et al.,
2008). EGFR signaling is normally conﬁned to the basal layer of the
epidermis where proliferating cells reside. Mice carrying a null
mutation in Egfr display a thin epidermis and abnormal differentiation
Fig. 7. AG1478 treatment suppresses precocious barrier formation and hyperproliferation in Fatp4mutants. Embryos were dissected at E16.5 from pregnant females injected i.p. with
AG1478 or vehicle (DMSO) daily for 2 days and tested for barrier integrity by X-Gal permeability assays (A) and for hyperproliferation by immunoﬂuorescence analyses (B and C).
(A) Both lateral (left panel) and dorsal (right panel) views of embryos are shown. Whereas DMSO-treated Fatp4 mutants displayed a precocious skin barrier over the entire body,
AG1478-treated mutants acquired only a slight barrier in the dorso-lateral region (arrowheads). Each caliber is 1 mm. (B) Dorsal skin sections of DMSO-treated mutant embryos
exhibited an increased number of Ki67-positive cells (green; arrowheads) in the suprabasal layer. Upon AG1478 treatment, hyperproliferation in the mutant skin was reduced.
Laminin γ1 (red) demarcates the dermo-epidermal boundary. Scale bar is 100 μm. (C) Upon AG1478 treatment, Fatp4mutant skin displayed a statistically signiﬁcant reduction in the
fold increase in proliferation, as compared to DMSO treatment (Pb0.01). The Y axis indicates fold increase in epidermal proliferation in Fatp4 mutants versus control littermates.
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mice overexpressing TGFα (an EGFR ligand) in the basal layer of the
epidermis exhibit scaly skin and epidermal hyperplasia (Vassar and
Fuchs, 1991), similar to Fatp4 mutants. However, in contrast to the
tight and wrinkle-free skin of Fatp4 mutants, TGFα transgenic mice
show increased skin wrinkling. This discrepancy may result from
induction and activation of the EGFR suprabasally in the Fatp4mutant
skin, but not in TGFα transgenic mice.
STAT3, an effector molecule for EGFR signaling, has previously
been implicated in remodeling of the skin. Mice lacking STAT3 in
epidermal keratinocytes display severe defects in wound healing and
hair cycling (Sano et al., 1999). In contrast, mice overexpressing
STAT3 in epidermis develop psoriasis-like phenotypes spontaneously
or in response to wounding (Sano et al., 2005). Along with ectopic
activation of STAT3 in suprabasal keratinocytes, Fatp4 mutant skin
exhibited upregulation of Icam1,Myc, Socs3, Adam8 (Table 1), and Bcl3
(data not shown), ﬁve direct targets of STAT3 (Caldenhoven et al.,
1995; Kiuchi et al., 1999; Snyder et al., 2008). However, although
AG1478 suppressed both STAT3 activation and epidermal hyperpro-
liferation, upregulation of these STAT3 targets was not suppressed, as
assayed by RT-qPCR (data not shown). It is therefore likely that the
drug-mediated remedy of epidermal hyperproliferation (and prema-
ture skin barrier formation) was exerted through suppression of other
STAT3 target genes or through other EGFR effectors. Nevertheless, our
results suggest that FATP4 plays a role in controlling keratinocyte
proliferation in normal embryos by negatively regulating EGFR/STAT3
signaling (Fig. 8).
Whereas AG1478-mediated suppression of STAT3 activation was
associated with drastic reductions in EGFR and JAK2 activation
(Fig. 5), curcumin only moderately reduced EGFR and JAK2 activation(Fig. 6). Despite suppressing hyperplasia, neither AG1478 nor
curcumin treatment remedied the ﬂat skin and sparse hair aspects
of the wrinkle free phenotype, implying that those abnormalities may
be attributable to deregulated expression of other signaling molecules
(Fig. 8). This also demonstrates the multipronged nature of the
phenotype.
Members of the interleukin 20 (IL-20) subfamily of cytokines,
including IL-19, -20, -22, and -24, have been shown to be upregulated
in human psoriatic skin and to be involved in the pathogenesis of
psoriasis (Sabat et al., 2007); they are able to induce expression of
psoriasis-associated proteins, activation of STAT3, hyperproliferation,
and abnormal differentiation of epidermal keratinocytes both in vivo
(Blumberg et al., 2001) and in vitro (Sa et al., 2007). Most of those
phenotypes are also found in Fatp4 mutants. Consistent with
activation of STAT3 by IL24 in human keratinocytes (Wang et al.,
2002), our data showed upregulation of IL24 and activation of STAT3
in mutant suprabasal keratinocytes (Figs. 3 and 4). Taken together,
our data indicate roles for cytokines (in addition to the EGFR) in
STAT3-mediated skin abnormalities in Fatp4 mutants (Fig. 8).
FATP4 and barrier formation
In addition to its effects on proliferation, the absence of FATP4 also
led to precocious establishment of a skin barrier. The early onset of
barrier formation reﬂected premature expression of barrier-relevant
genes, including members of the epidermal differentiation complex.
Nevertheless, the barrier never progressed to completion. Interest-
ingly, we did not ﬁnd upregulated expression of Klf4, which encodes a
transcription factor that positively regulates the expression of barrier
genes in suprabasal keratinocytes (Jaubert et al., 2003; Patel et al.,
Fig. 8. Mechanisms by which Fatp4 mutation affects the development of skin. Our data suggest discrete mechanisms for the distinct skin phenotypes of Fatp4 mutants. The
incomplete barrier in Fatp4mutants may be due to direct effects of the lack of FATP4 on the lipid-enriched lamellar membrane that seals the intercellular spaces of the corniﬁed layer.
Activation of STAT3 through pathways involving EGF family ligands and cytokines likely accounts for the epidermal hyperplasia/hyperproliferation and premature barrier formation
in Fatp4 mutants, though other downstream effectors of EGFR activation may also be involved. Blockage of EGFR/STAT3 activation by either AG1478 or curcumin remedied
epidermal hyperplasia/hyperproliferation and suppressed premature barrier formation. However, neither AG1478 nor curcumin treatment remedied the tight and wrinkle-free skin
and sparse hair phenotypes, which may be mediated by other pathways. It remains unclear how altered lipid metabolism in Fatp4 mutants initiates the observed alterations in
epidermal signaling pathways.
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initiates premature barrier formation independent of increased Klf4
expression. On the other hand, the cellular environment created by
the absence of FATP4 may lead to premature activation of KLF4-
mediated transcription, perhaps due to increased expression of a
required cofactor.
Suppression of EGFR and STAT3 activation by AG1478 and
curcumin inhibited precocious barrier formation in Fatp4 mutants
(Fig. 7 and data not shown), suggesting that FATP4 somehow
negatively regulates EGFR/STAT3 signaling to temporally control
barrier initiation in normal embryos. However, that AG1478 treat-
ment did not remedy the incomplete barrier phenotype at later stages
suggests that there are EGFR/STAT3-independent roles for FATP4
(Fig. 8). In support of this, Fatp4−/− epidermis exhibits reduced levels
of ceramides containing very long chain fatty acids (Herrmann et al.,
2003; Moulson et al., 2007), which are crucial for normal barrier
integrity (Feingold, 2007). The observed inability of the precocious
barrier to progress to a complete barrier is likely due directly to the
effects of the lack of FATP4 on the formation or composition of the
lipid-enriched lamellar membrane that seals the intercellular spaces
of the corniﬁed layer.
How does FATP4 activity inﬂuence keratinocyte proliferation and
differentiation?
The analysis presented here has provided important new insights
into the mechanisms leading to the wrinkle free skin phenotype. But
why the absence of FATP4 initiates the cascade of events that causes
the phenotype remains to be determined. FATP4 has been reported to
exhibit ACS activity (Hall et al., 2005; Herrmann et al., 2001; Jia et al.,
2007; Milger et al., 2006), and we recently showed that FATP4 with
mutations in its ACS domain fail to rescue the wrinkle free phenotype(Moulson et al., 2007). Furthermore, Fatp4−/− skin ﬁbroblasts show
an impaired ability to esterify C24:0 to CoA (Jia et al., 2007). It is
therefore possible that the lack of FATP4 activity results in
accumulation of free, unesteriﬁed fatty acids that serve as ligands to
activate signaling pathways disruptive to normal skin development.
Free fatty acids are ligands for peroxisome proliferator-activated
receptors (PPARs), whose activation promotes keratinocyte differen-
tiation and barrier formation (Di-Poi et al., 2004; Komuves et al.,
1998; Schmuth et al., 2004). To test if the lack of FATP4 leads to
aberrant keratinocyte differentiation via overactivation of PPAR
signaling, we generated mice lacking both FATP4 and either PPARα
or PPARβ/δ (Lee et al., 1995; Peters et al., 2000). However, Fatp4
mutants lacking either PPARα or PPARβ/δ still died perinatally and
did not show any changes in their wrinkle free phenotype (MHL and
JHM, unpublished results). These results suggest that the Fatp4
phenotype is not due to overactivation of PPAR signaling by an
elevated level of free fatty acids, though it would be interesting to
determine whether elimination of both PPARα and PPARβ/δ
activation would ameliorate the skin defects.
That there are already extensive changes in keratinocyte gene
expression in Fatp4−/− embryos by E15.5 suggests that FATP4 must
have crucial functions at even earlier stages of development. FATP4
also has later roles in promoting barrier formation and hair and
sebaceous gland maturation and function (Moulson et al., 2007; MHL
and JHM, unpublished observations). Thus, FATP4 has multiple,
separable roles in the development and function of skin and its
appendages, presumably via direct effects on lipid metabolism and
homeostasis that we are currently investigating. A more complete
understanding of FATP4 biology will provide important insights into
the pathophysiology of ichthyosis prematurity syndrome, an autoso-
mal recessive congenital disorder caused by FATP4 mutations that
leads to premature birth, respiratory distress, and edematous skin
718 M.-H. Lin et al. / Developmental Biology 344 (2010) 707–719with severe ichthyotic scaling (Klar et al., 2009). It will be interesting
to determine whether these patients show defects in epidermal
proliferation and lipid metabolism that are similar to those observed
in Fatp4 mutant mice.
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